MX2022010926A - Compuestos para su uso en infecciones viricas. - Google Patents

Compuestos para su uso en infecciones viricas.

Info

Publication number
MX2022010926A
MX2022010926A MX2022010926A MX2022010926A MX2022010926A MX 2022010926 A MX2022010926 A MX 2022010926A MX 2022010926 A MX2022010926 A MX 2022010926A MX 2022010926 A MX2022010926 A MX 2022010926A MX 2022010926 A MX2022010926 A MX 2022010926A
Authority
MX
Mexico
Prior art keywords
compounds
viral infections
virus
treatment
viral infection
Prior art date
Application number
MX2022010926A
Other languages
English (en)
Inventor
Marín Pablo Avilés
González Alejandro Losada
Sousa-Faro José María Fernández
Muñoz Salvador Fudio
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MX2022010926A publication Critical patent/MX2022010926A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al uso de compuestos en el tratamiento de una infección vírica, en donde el virus se selecciona entre la familia Orthomyxoviridae o en donde el virus es el virus del Nilo occidental.
MX2022010926A 2020-03-02 2021-03-02 Compuestos para su uso en infecciones viricas. MX2022010926A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP20382152 2020-03-02
EP20382192 2020-03-13
EP20382266 2020-04-02
EP20382339 2020-04-27
EP20382815 2020-09-16
EP20382816 2020-09-16
EP21382059 2021-01-25
PCT/EP2021/055147 WO2021175831A2 (en) 2020-03-02 2021-03-02 Compounds for use in viral infections

Publications (1)

Publication Number Publication Date
MX2022010926A true MX2022010926A (es) 2022-09-29

Family

ID=74732953

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2022010921A MX2022010921A (es) 2020-03-02 2021-03-02 Compuestos para su uso en afecciones inflamatorias.
MX2022010926A MX2022010926A (es) 2020-03-02 2021-03-02 Compuestos para su uso en infecciones viricas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2022010921A MX2022010921A (es) 2020-03-02 2021-03-02 Compuestos para su uso en afecciones inflamatorias.

Country Status (16)

Country Link
US (2) US20230295236A1 (es)
EP (2) EP4114435A1 (es)
JP (2) JP2023517535A (es)
KR (2) KR20220151643A (es)
CN (2) CN115666616A (es)
AU (2) AU2021231197A1 (es)
BR (2) BR112022016604A2 (es)
CA (2) CA3169540A1 (es)
CL (2) CL2022002396A1 (es)
CO (2) CO2022014031A2 (es)
IL (2) IL296069A (es)
MX (2) MX2022010921A (es)
PE (2) PE20230606A1 (es)
TW (2) TW202146038A (es)
UY (2) UY39109A (es)
WO (2) WO2021175831A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117285611B (zh) * 2023-11-24 2024-02-09 中国海洋大学 一种来源于海鞘的抗炎寡肽及其在制备药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
AU2001251498A1 (en) 2000-04-07 2001-10-23 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
MXPA05010064A (es) 2003-03-21 2006-05-17 Madeleine M Joullie Analogos de tamandarin y fragmentos de los mismos y metodos para hacerlos y usarlos.
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds

Also Published As

Publication number Publication date
IL296069A (en) 2022-11-01
JP2023517535A (ja) 2023-04-26
TW202144381A (zh) 2021-12-01
EP4114435A1 (en) 2023-01-11
MX2022010921A (es) 2022-09-29
AU2021231197A1 (en) 2022-10-06
CO2022014031A2 (es) 2022-10-21
WO2021175831A3 (en) 2021-10-14
US20230159594A1 (en) 2023-05-25
CL2022002395A1 (es) 2023-06-30
US20230295236A1 (en) 2023-09-21
WO2021175857A1 (en) 2021-09-10
UY39110A (es) 2021-09-30
KR20220151643A (ko) 2022-11-15
IL296068A (en) 2022-11-01
PE20230606A1 (es) 2023-04-10
CA3169544A1 (en) 2021-09-10
PE20230412A1 (es) 2023-03-07
BR112022016604A2 (pt) 2022-10-11
TW202146038A (zh) 2021-12-16
EP4114433A2 (en) 2023-01-11
BR112022016675A2 (pt) 2022-10-11
CL2022002396A1 (es) 2023-06-30
CA3169540A1 (en) 2021-09-10
CO2022014093A2 (es) 2022-11-18
CN115666616A (zh) 2023-01-31
WO2021175831A2 (en) 2021-09-10
UY39109A (es) 2021-09-30
KR20220150350A (ko) 2022-11-10
AU2021232535A1 (en) 2022-10-06
CN115461067A (zh) 2022-12-09
JP2023517536A (ja) 2023-04-26

Similar Documents

Publication Publication Date Title
PH12019500335A1 (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
PH12020550531A1 (en) Novel, highly active pyrazolo-piperidine substituted indole2-carboxamides active against the hepatitis b virus (hbv)
PH12018500931A1 (en) Hcv polymerase inhibitors
PH12016501631A1 (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
PH12020550525A1 (en) Novel, highly active amino-thiazole substituted indole-2carboxamides active against the hepatitis b virus (hbv)
MX2018005230A (es) Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon.
WO2011000566A3 (en) Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
MY141003A (en) Materials and methods for treating viral infections with a cysteamine compound
MX2022016066A (es) Nuevo inhibidor de proteina-cinasa-cinasa activada por mitogeno (mek) para el tratamiento de infecciones virales y bacterianas.
MX2022010926A (es) Compuestos para su uso en infecciones viricas.
MX2021012604A (es) Nuevo inhibidor de mek para el tratamiento de infecciones virales y bacterianas.
MX2022013814A (es) Tratamiento de infecciones virales.
MX2021013085A (es) Nuevas indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb).
MX2021016005A (es) Derivados de aminas terciarias y sus usos para tratar una infección vírica.
MX2021013105A (es) Nuevas oxalil piperazinas activas contra el virus de la hepatitis b (vhb).
EA202192965A1 (ru) Новые индолизин-2-карбоксамиды, активные против вируса гепатита b (вгв)
EA202192967A1 (ru) Новые индол-2-карбоксамиды, активные против вируса гепатита b (вгв)
EA201990295A1 (ru) Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич